Voluntis Obtains €2 Million in Non-dilutive Financing
14 Settembre 2020 - 6:00PM
Business Wire
- Voluntis obtains a state-guaranteed loan of €2 million from
BNP Paribas.
- The new loan will contribute to the financing of the
company’s growth initiatives in line with its strategic
roadmap.
Regulatory News:
Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a
leader in digital therapeutics, announces today that it has
obtained a state-guaranteed loan (Prêt Garanti par l’Etat, or PGE
in France) from BNP Paribas.
This €2 million loan has an initial term of one year is fully
repayable on maturity1. Repayment of the amounts due may be
deferred again, at the company's option, until September 2026. The
French State guarantees 90% of the amounts due.
This loan, which is non-dilutive to shareholders, carries a
fixed annual interest rate of 0.25% for the first year2.
“We are glad to announce this new loan from BNP Paribas” said
Pierre Leurent, CEO of Voluntis. “This non-dilutive cash injection
further reinforces our financial situation and will contribute to
our growth initiatives in the digital therapeutics space in line
with our strategic roadmap.”
Voluntis is also continuing to study various complementary
options to cover its residual financing needs for the next 12
months, estimated at €2 million, including the signature of new
partnerships that could generate short-term invoicing, additional
financing to the PGE currently under discussion with Bpifrance as
part of the new government support measures for companies during
the Covid-19 crisis or the implementation of the OCEANE-BSA program
granted by Alpha Blue Ocean in the first quarter of 2020.
About Voluntis
Voluntis creates digital therapeutics that empower people
suffering from chronic conditions to self-manage their treatment
every day, thus improving real-world outcomes. Combining mobile and
web apps, and using clinical algorithms, Voluntis’ solutions
deliver personalized recommendations to the patient and the care
team so that they can, for example, adjust treatment dosage, manage
side effects or monitor symptoms. Leveraging its Theraxium
technology platform, Voluntis has designed and operates multiple
digital therapeutics, especially in diabetes and oncology. Voluntis
has long-standing partnerships with leading life science companies.
Based out of Boston and Paris, France, Voluntis is a founding
member of the Digital Therapeutics Alliance. For more information,
please visit: www.voluntis.com
Mnemo : VTX - ISIN : FR0004183960
Disclaimer
This press release contains certain forward-looking statements
concerning Voluntis group and its business, including its prospects
and product candidate development. Such forward-looking statements
are based on assumptions that Voluntis considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
reference document of Voluntis registered with the French Financial
Markets Authority (Autorité des Marchés Financiers) under number
R.19-013 on April 26, 2019 (a copy of which is available on
www.voluntis.com) and to the development of economic conditions,
financial markets and the markets in which Voluntis operates. The
forward-looking statements contained in this press release are also
subject to risks not yet known to Voluntis or not currently
considered material by Voluntis. The occurrence of all or part of
such risks could cause actual results, financial conditions,
performance or achievements of Voluntis to be materially different
from such forward-looking statements. Voluntis expressly declines
any obligation to update such forward-looking statements.
_____________________
1 Except in the usual cases of early repayment (non-payment,
collective proceedings, non-compliance with one of the contractual
obligations, etc.). 2 This interest rate may change in subsequent
years, should the Company decide to defer the repayment of the
principal for the next five years, provided that in any event, it
may not exceed a percentage corresponding to the bank's refinancing
cost at the date of the deferral plus the State guarantee
commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200914005463/en/
ACTUS Media relations Vivien Ferran vferran@actus.fr +33
(0)1 53 67 36 34
ACTUS Investor relations Jérôme Fabreguettes-Leib
voluntis@actus.fr +33 (0)1 53 67 36 78
Voluntis Directeur Administratif et Financier Guillaume
Floch investisseurs@voluntis.com +33 (0)1 41 38 39 20